American Journal of Hematology
Fecha de publicación: 10 January 2018
Autores: Philip A. Stevenson, Brent L. Wood, Pamela S. Becker, Paul C. Hendrie, Brenda M. Sandmaier, Jerald L. Radich, Andrei R. Shustov.
Background: HyperCVAD is a commonly‐used regimen for adults with newly‐diagnosed acute lymphoblastic leukemia (ALL). However, relatively little is known about the application of minimal residual disease (MRD) detection with this treatment. To address this, we studied 142 adults with ALL treated with hyperCVAD over a 10‐year period who had MRD assessed by either multi‐parameter flow cytometry or (for patients with Philadelphia chromosome positive ALL) reverse transcriptase polymerase chain reaction for the BCR‐ABL1 translocation.